Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joan Reibman

Pulmonary Disease New York, NY Medical Doctor

NPI 1265649933 CMS profile 428451

550 1St Ave, Room Bh7n24, New York, NY 10016

Open in the dashboard

General payments

$73,324

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$218,877 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Joan Reibman of New York, NY is reported in the CMS Open Payments database as having received $73,324 across 66 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $218,877 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,074 1
2023 General $115 1
2022 General $9,712 5
2021 General $12,351 8
2020 General $20,722 17
2019 General $29,349 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joan Reibman
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Joan Reibman were reported at $1,074. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Joan Reibman Pulmonary Disease median Middle half National median
2019 $29,349 $377 $109–$1,340 $163
2020 $20,722 $230 $56–$907 $114
2021 $12,351 $269 $68–$1,072 $132
2022 $9,712 $390 $100–$1,457 $149
2023 $115 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $1,074 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $65,748 62 payments
  2. Novartis Pharmaceuticals Corporation $4,576 2 payments
  3. AstraZeneca AB $2,954 1 payment
  4. Regeneron Healthcare Solutions, Inc. $46 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $70,091 39 payments
  2. Travel and Lodging $1,959 7 payments
  3. Food and Beverage $912 17 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $300 1 payment
  5. Education $62 2 payments
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $36,587 41 payments
  2. FASENRA Respiratory $15,036 9 payments
  3. DUPIXENT $46 1 payment
  4. BREZTRI AEROSPHERE $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

787

Median for Internal Medicine: 777

Drug cost

$288,741

Median for Internal Medicine: $73,373

Branded share of claims

58.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 18 $70,988
Nucala Mepolizumab Brand 15 $57,313
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $32,475
Xolair Omalizumab Brand 18 $31,486
Spiriva Respimat Tiotropium Bromide Brand 42 $26,486
Symbicort Budesonide/Formoterol Fumarate Brand 55 $18,190
Breo Ellipta Fluticasone/Vilanterol Brand 17 $11,671
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 49 $9,147
Incruse Ellipta Umeclidinium Bromide Brand 12 $7,708
Advair Hfa Fluticasone Propion/Salmeterol Brand 13 $7,313

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record